Video

Dr. Kundranda on the Need for Novel Treatments in Pancreatic Ductal Adenocarcinoma

Madappa Kundranda, MD, PhD, discusses the need ​to develop novel treatments in pancreatic ductal adenocarcinoma.

Madappa Kundranda, MD, PhD, director, Gastrointestinal Oncology Program, deputy chief, Division of Medical Oncology, Banner MD Anderson Cancer Center, discusses the need ​to develop novel treatments in pancreatic ductal adenocarcinoma (PDAC). 

​The current standards of care in PDAC are not sufficient, says Kundranda. As such, patients ​with PDAC, particularly those with a good performance status, should have the opportunity to participate in clinical trial​s.

​There are several ongoing trials ​in the pancreatic cancer paradigm, ​including the phase 3 NAPOLI-1 and AVENGER 500 studies, Kundranda explains. 

Furthermore, ​data evaluating the utility of ​neoadjuvant FOLFIRINOX versus gemcitabine plus nab-paclitaxel ​(Abraxane) in patients with resectable or borderline resectable pancreatic cancer were presented at the 2020 ASCO Virtual Scientific Program.

Ultimately, these data suggest that a triplet regimen might not be superior to a doublet, Kundranda concludes. 

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Expert Perspectives on Applying Recent Evidence to Practice in the Management of Newly Diagnosed Multiple Myeloma
Video

Expert Perspectives on Applying Recent Evidence to Practice in the Management of Newly Diagnosed Multiple Myeloma

Jun 19th 2025 - Jul 25th 2025

online-activity
Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies
Audio

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

Jun 18th 2025 - Jun 19th 2026

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity